Astellas Pharma (Astellas Pharma) 3-Year Book Growth Rate : 6.50% (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Astellas Pharma 3-Year Book Growth Rate?

Astellas Pharma's Book Value per Share for the quarter that ended in Dec. 2023 was $5.82.

During the past 12 months, Astellas Pharma's average Book Value per Share Growth Rate was -2.50% per year. During the past 3 years, the average Book Value per Share Growth Rate was 6.50% per year. During the past 5 years, the average Book Value per Share Growth Rate was 5.80% per year. During the past 10 years, the average Book Value per Share Growth Rate was 4.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Astellas Pharma was 10.90% per year. The lowest was 1.10% per year. And the median was 4.10% per year.

Competitive Comparison of Astellas Pharma's 3-Year Book Growth Rate

For the Drug Manufacturers - General subindustry, Astellas Pharma's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Astellas Pharma's 3-Year Book Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's 3-Year Book Growth Rate falls into.

Astellas Pharma 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Astellas Pharma (OTCPK:ALPMY) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Astellas Pharma 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Astellas Pharma (Astellas Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMY) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

ALPMF:USA 4503:Mexico 4503:Japan YPHA:Germany

Address

2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411

Website

http://www.astellas.com

Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.